vs

Side-by-side financial comparison of P3 Health Partners Inc. (PIII) and PHOTRONICS INC (PLAB). Click either name above to swap in a different company.

P3 Health Partners Inc. is the larger business by last-quarter revenue ($384.8M vs $210.4M, roughly 1.8× PHOTRONICS INC). PHOTRONICS INC runs the higher net margin — 10.9% vs -19.6%, a 30.5% gap on every dollar of revenue. On growth, P3 Health Partners Inc. posted the faster year-over-year revenue change (3.8% vs -5.5%). Over the past eight quarters, P3 Health Partners Inc.'s revenue compounded faster (-0.5% CAGR vs -3.8%).

P3 Health Partners Inc. is a population health management and value-based care services firm operating primarily in the United States. It partners with primary care providers and health systems to deliver coordinated, high-quality care for patient populations, especially Medicare Advantage beneficiaries, focusing on improving health outcomes and lowering unnecessary healthcare costs.

Photronics, Inc. is an American semiconductor photomask manufacturer. It was the third largest photomask supplier globally as of 2009. Photronics is a member of the eBeam Initiative.

PIII vs PLAB — Head-to-Head

Bigger by revenue
PIII
PIII
1.8× larger
PIII
$384.8M
$210.4M
PLAB
Growing faster (revenue YoY)
PIII
PIII
+9.3% gap
PIII
3.8%
-5.5%
PLAB
Higher net margin
PLAB
PLAB
30.5% more per $
PLAB
10.9%
-19.6%
PIII
Faster 2-yr revenue CAGR
PIII
PIII
Annualised
PIII
-0.5%
-3.8%
PLAB

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
PIII
PIII
PLAB
PLAB
Revenue
$384.8M
$210.4M
Net Profit
$-75.5M
$22.9M
Gross Margin
33.7%
Operating Margin
-40.0%
22.9%
Net Margin
-19.6%
10.9%
Revenue YoY
3.8%
-5.5%
Net Profit YoY
-28.8%
-32.4%
EPS (diluted)
$-23.08
$0.39

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PIII
PIII
PLAB
PLAB
Q4 25
$384.8M
Q3 25
$345.3M
$210.4M
Q2 25
$355.8M
$211.0M
Q1 25
$373.2M
$212.1M
Q4 24
$370.7M
$222.6M
Q3 24
$362.1M
$211.0M
Q2 24
$379.2M
$217.0M
Q1 24
$388.5M
$216.3M
Net Profit
PIII
PIII
PLAB
PLAB
Q4 25
$-75.5M
Q3 25
$-31.6M
$22.9M
Q2 25
$-20.4M
$8.9M
Q1 25
$-20.5M
$42.9M
Q4 24
$-58.6M
$33.9M
Q3 24
$-46.5M
$34.4M
Q2 24
$-12.0M
$36.3M
Q1 24
$-18.7M
$26.2M
Gross Margin
PIII
PIII
PLAB
PLAB
Q4 25
Q3 25
33.7%
Q2 25
36.9%
Q1 25
35.6%
Q4 24
37.0%
Q3 24
35.6%
Q2 24
36.5%
Q1 24
36.6%
Operating Margin
PIII
PIII
PLAB
PLAB
Q4 25
-40.0%
Q3 25
-12.8%
22.9%
Q2 25
-9.6%
26.4%
Q1 25
-10.2%
24.6%
Q4 24
-37.4%
25.1%
Q3 24
-29.5%
24.7%
Q2 24
-8.3%
25.8%
Q1 24
-11.3%
26.6%
Net Margin
PIII
PIII
PLAB
PLAB
Q4 25
-19.6%
Q3 25
-9.1%
10.9%
Q2 25
-5.7%
4.2%
Q1 25
-5.5%
20.2%
Q4 24
-15.8%
15.2%
Q3 24
-12.8%
16.3%
Q2 24
-3.2%
16.7%
Q1 24
-4.8%
12.1%
EPS (diluted)
PIII
PIII
PLAB
PLAB
Q4 25
$-23.08
Q3 25
$-9.67
$0.39
Q2 25
$-6.23
$0.15
Q1 25
$-6.28
$0.68
Q4 24
$-23.13
$0.54
Q3 24
$-15.70
$0.55
Q2 24
$-7.37
$0.58
Q1 24
$-7.86
$0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PIII
PIII
PLAB
PLAB
Cash + ST InvestmentsLiquidity on hand
$25.0M
$575.8M
Total DebtLower is stronger
$228.4M
$16.0K
Stockholders' EquityBook value
$-155.2M
$1.1B
Total Assets
$656.6M
$1.8B
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PIII
PIII
PLAB
PLAB
Q4 25
$25.0M
Q3 25
$37.7M
$575.8M
Q2 25
$38.6M
$558.4M
Q1 25
$40.1M
$642.2M
Q4 24
$38.8M
$640.7M
Q3 24
$63.0M
$606.4M
Q2 24
$73.1M
$559.9M
Q1 24
$27.3M
$521.5M
Total Debt
PIII
PIII
PLAB
PLAB
Q4 25
$228.4M
Q3 25
$252.8M
$16.0K
Q2 25
$182.0M
$19.0K
Q1 25
$171.1M
$21.0K
Q4 24
$108.9M
$25.0K
Q3 24
$133.2M
$28.0K
Q2 24
$133.1M
$2.5M
Q1 24
$118.1M
$2.7M
Stockholders' Equity
PIII
PIII
PLAB
PLAB
Q4 25
$-155.2M
Q3 25
$-18.7M
$1.1B
Q2 25
$44.5M
$1.1B
Q1 25
$63.3M
$1.1B
Q4 24
$75.9M
$1.1B
Q3 24
$120.5M
$1.1B
Q2 24
$166.8M
$1.0B
Q1 24
$146.6M
$1.0B
Total Assets
PIII
PIII
PLAB
PLAB
Q4 25
$656.6M
Q3 25
$683.6M
$1.8B
Q2 25
$731.6M
$1.7B
Q1 25
$783.9M
$1.7B
Q4 24
$783.4M
$1.7B
Q3 24
$833.3M
$1.6B
Q2 24
$892.8M
$1.6B
Q1 24
$855.9M
$1.6B
Debt / Equity
PIII
PIII
PLAB
PLAB
Q4 25
Q3 25
0.00×
Q2 25
4.09×
0.00×
Q1 25
2.71×
0.00×
Q4 24
1.43×
0.00×
Q3 24
1.11×
0.00×
Q2 24
0.80×
0.00×
Q1 24
0.81×
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PIII
PIII
PLAB
PLAB
Operating Cash FlowLast quarter
$-25.7M
$50.1M
Free Cash FlowOCF − Capex
$25.2M
FCF MarginFCF / Revenue
12.0%
Capex IntensityCapex / Revenue
11.8%
Cash ConversionOCF / Net Profit
2.19×
TTM Free Cash FlowTrailing 4 quarters
$64.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PIII
PIII
PLAB
PLAB
Q4 25
$-25.7M
Q3 25
$-15.4M
$50.1M
Q2 25
$-16.6M
$31.5M
Q1 25
$-33.5M
$78.5M
Q4 24
$-57.2M
$68.4M
Q3 24
$-22.6M
$75.1M
Q2 24
$-10.2M
$76.5M
Q1 24
$-20.0M
$41.5M
Free Cash Flow
PIII
PIII
PLAB
PLAB
Q4 25
Q3 25
$25.2M
Q2 25
$-29.1M
Q1 25
$43.3M
Q4 24
$25.2M
Q3 24
$50.7M
Q2 24
$56.5M
Q1 24
$-1.8M
FCF Margin
PIII
PIII
PLAB
PLAB
Q4 25
Q3 25
12.0%
Q2 25
-13.8%
Q1 25
20.4%
Q4 24
11.3%
Q3 24
24.0%
Q2 24
26.0%
Q1 24
-0.8%
Capex Intensity
PIII
PIII
PLAB
PLAB
Q4 25
Q3 25
11.8%
Q2 25
28.7%
Q1 25
16.6%
Q4 24
0.0%
19.4%
Q3 24
0.0%
11.6%
Q2 24
0.0%
9.2%
Q1 24
0.0%
20.0%
Cash Conversion
PIII
PIII
PLAB
PLAB
Q4 25
Q3 25
2.19×
Q2 25
3.55×
Q1 25
1.83×
Q4 24
2.02×
Q3 24
2.18×
Q2 24
2.11×
Q1 24
1.59×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PIII
PIII

Capitated Revenue$366.2M95%
Health Care Patient Service$18.6M5%
Health Care Care Coordination Management Fees$2.7M1%

PLAB
PLAB

High End Integrated Circuits$53.6M25%
High End Flat Panel Displays$53.5M25%
KR$43.7M21%
Other$42.1M20%
Mainstream Flat Panel Displays$9.1M4%
Transferred At Point In Time$8.4M4%

Related Comparisons